In instances where obesity is considered a risk factor and an exacerbator of disease, the additional weight gain due to anti-IL-6 administration may be an undesirable effect, and given the well-documented detrimental effects associated with obesity (e.g., cardiovascular disease, metabolic syndrome, mental health problems [54,55,56]), prescribers should take this into consideration when administering IL-6 pathway inhibitors. This evidence concerns the gene IL6 and metabolic syndrome.